Fjarde AP Fonden Fourth Swedish National Pension Fund Sells 11,000 Shares of Cencora, Inc. $COR

Fjarde AP Fonden Fourth Swedish National Pension Fund cut its holdings in Cencora, Inc. (NYSE:COR) by 8.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 118,677 shares of the company’s stock after selling 11,000 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Cencora were worth $40,083,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the business. Parallel Advisors LLC increased its stake in shares of Cencora by 3.7% in the fourth quarter. Parallel Advisors LLC now owns 6,452 shares of the company’s stock worth $2,179,000 after purchasing an additional 229 shares in the last quarter. Deseret Mutual Benefit Administrators increased its stake in shares of Cencora by 17.9% in the fourth quarter. Deseret Mutual Benefit Administrators now owns 805 shares of the company’s stock worth $272,000 after purchasing an additional 122 shares in the last quarter. Vise Technologies Inc. increased its stake in shares of Cencora by 94.4% in the fourth quarter. Vise Technologies Inc. now owns 8,288 shares of the company’s stock worth $2,799,000 after purchasing an additional 4,024 shares in the last quarter. Daiwa Securities Group Inc. increased its stake in shares of Cencora by 9.6% in the fourth quarter. Daiwa Securities Group Inc. now owns 32,629 shares of the company’s stock worth $11,021,000 after purchasing an additional 2,849 shares in the last quarter. Finally, State of Wyoming increased its stake in shares of Cencora by 638.3% in the fourth quarter. State of Wyoming now owns 1,447 shares of the company’s stock worth $489,000 after purchasing an additional 1,251 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors.

Cencora Stock Performance

COR opened at $274.94 on Friday. The stock has a market capitalization of $53.49 billion, a price-to-earnings ratio of 21.08, a PEG ratio of 1.46 and a beta of 0.59. The company has a fifty day moving average of $292.70 and a 200 day moving average of $330.55. Cencora, Inc. has a fifty-two week low of $244.82 and a fifty-two week high of $377.54. The company has a debt-to-equity ratio of 3.40, a quick ratio of 0.59 and a current ratio of 0.95.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing the consensus estimate of $4.82 by ($0.07). The company had revenue of $78.36 billion for the quarter, compared to analysts’ expectations of $81.09 billion. Cencora had a net margin of 0.78% and a return on equity of 135.20%. The business’s revenue was up 3.9% on a year-over-year basis. During the same period in the previous year, the business posted $4.42 earnings per share. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. As a group, sell-side analysts forecast that Cencora, Inc. will post 17.79 earnings per share for the current fiscal year.

Cencora declared that its board has approved a stock buyback plan on Thursday, May 21st that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the company to reacquire up to 3.9% of its stock through open market purchases. Stock buyback plans are usually a sign that the company’s leadership believes its shares are undervalued.

Cencora Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, June 1st. Investors of record on Friday, May 15th were paid a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend was Friday, May 15th. Cencora’s dividend payout ratio (DPR) is presently 18.40%.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Leerink Partners reissued an “outperform” rating on shares of Cencora in a research note on Tuesday, March 17th. Barclays increased their price objective on shares of Cencora from $400.00 to $425.00 and gave the stock an “overweight” rating in a research note on Friday, February 13th. Robert W. Baird reduced their price objective on shares of Cencora from $420.00 to $339.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Wells Fargo & Company reduced their price objective on shares of Cencora from $429.00 to $331.00 and set an “overweight” rating for the company in a research note on Monday, May 11th. Finally, Weiss Ratings cut shares of Cencora from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday, May 22nd. Twelve equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, Cencora presently has a consensus rating of “Moderate Buy” and a consensus target price of $380.25.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.